Home Induction and Outpatient Treatment of Kratom use Disorder with Buprenorphine-Naloxone: A Case Report in a Young Adult

Abstract

Background: The use of the natural product, kratom, has increased significantly in recent years. The active compounds in kratom have been shown to produce both opioid and stimulant-like effects. While kratom is marketed as a safe, non-addictive method to treat pain and opioid withdrawal, there have been reports demonstrating that kratom is physiologically addictive and linked to overdose deaths. A limited number of case-reports are available describing treatment of kratom use disorder in middle-aged adults, generally in the context of chronic pain and in inpatient settings. Our case is unique in that we describe outpatient treatment of kratom use disorder in a young adult with comorbid attention deficit hyperactivity disorder (ADHD) and in the absence of chronic pain.

Case: A 20-year-old college student with ADHD presented to an office-based opioid agonist treatment clinic (OBOT) for treatment of kratom use disorder. He was unable to attend inpatient or residential substance use treatment due to work and school obligations. Additionally, he had stopped taking his prescribed stimulant due to cardiac side effects. The OBOT team successfully initiated buprenorphine-naloxone (BUP/NAL) sublingual films via home induction to treat his kratom use disorder. The patient is being monitored monthly with plans to slowly taper his BUP/NAL dose as tolerated.

Discussion: We present a case of a young adult male with kratom use disorder, complicated by a diagnosis of ADHD, successfully treated with BUP/NAL via home induction. The patient is currently kratom-free, reports improved mood and sleep patterns since initiating BUP/NAL, and is able to once again tolerate his ADHD stimulant medication. Healthcare providers should be aware of the use of kratom and consider utilizing BUP/NAL to treat dependence to this botanical drug.

Keywords

Kratom Mitragyna speciosa adolescence buprenorphine-naloxone substance use

Get full access to this article

View all access options for this article.

References

Prozialeck

, Jivan

, Andurkar

. Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. J Am Osteopath Assoc. 2012;112(12):792–799.

Gershman

, Timm

, Frank

. Deaths in Colorado attributed to kratom. N Engl J Med. 2019;380(1):97–98.

Kuehn

. Kratom-related deaths. J Am Med Assoc. 2019;321(20):1966.

, Goggin

, Janis

. Analysis of mitragynine and metabolites in human urine for detecting the use of the psychoactive plant kratom. J Anal Toxicol. 2012;36(9):616–625.

Overbeek

, Abraham

, Munzer

. Kratom (mitragynine) ingestion requiring naloxone reversal. Clin Pract Cases Emerg Med. 2019;3(1):24–26.

Buresh

. Treatment of kratom dependence with buprenorphine-naloxone maintenance. J Addict Med.2018;12(6):481–483.

Khazaeli

, Jerry

, Vazirian

. Treatment of kratom withdrawal and addiction with buprenorphine. J Addict Med. 2018;12(6):493–495.

Smid

, Charles

, Gordon

, Wright

. Use of kratom, an opioid-like traditional herb, in pregnancy. Obstet Gynecol. 2018;132(4):926–928.

Babu

, Brent

, Juurlink

. Prevention of opioid overdose. N Engl J Med. 2019;380(23):2246–2255.

10.

U.S. Food and Drug Administration. FDA issues warnings to companies selling illegal, unapproved kratom drug products marketed for opioid cessation, pain treatment and other medical uses. https://www.fda.gov/news-events/press-announcements/fda-issues-warnings-companies-selling-illegal-unapproved-kratom-drug-products-marketed-opioid. Accessed July 19, 2019.

11.

Post

, Spiller

, Chounthirath

, Smith

. Kratom exposures reported to United States poison control centers: 2011–2017. Clin Toxicol (Phila). 2019;57(10):847–854.

12.

U.S. Food and Drug Administration. FDA and kratom. https://www.fda.gov/news-events/public-health-focus/fda-and-kratom. Accessed May 10, 2019.

13.

Drug Enforcement Administration US. Drugs of abuse: a DEA resource guide. https://www.dea.gov/sites/default/files/sites/getsmartaboutdrugs.com/files/publications/DoA_2017Ed_Updated_6.16.17.pdf#page=84. Accessed May 10, 2019.

14.

Throckmorton

, Gottlieb

, Woodcock

. The FDA and the next wave of drug abuse – proactive pharmacovigilance. N Engl J Med. 2018;379(3):205–207.

15.

Matson

, Hobson

, Abdel-Rasoul

, Bonny

. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic. J Addict Med. 2014;8(3):176–182.

16.

Olsen

, O'Donnell

, Mattson

, Schier

, Wilson

. Notes from the field: unintentional drug overdose deaths with kratom detected – 27 states, July 2016–December 2017. Mmwr Morb Mortal Wkly Rep. 2019;68(14):326–327.

17.

Smith

, Bunting

, Walker

, Hall

, Grundmann

, Castillo

. Non-prescribed buprenorphine use mediates the relationship between heroin use and kratom use among a sample of polysubstance users. J Psychoactive Drugs. 2019;1–12. [epub ahead of print].

18.

Likhitsathian

, Jiraporncharoen

, Aramrattana

, . Polydrug use among kratom users: findings from the 2011 Thailand National Household Survey. J Subst Use. 2018;23(4):384–389.

19.

National Institutes of Health. What complementary and integrative approaches do Americans use? Key findings from the 2012 National Health Interview Survey. https://nccih.nih.gov/research/statistics/NHIS/2012/key-findings. Accessed May 10, 2019.

20.

Barry

. Patients’ perceptions and use of natural health products. Can Pharm J (Ott). 2018;151(4):254–262.

21.

Bent

. Herbal medicine in the United States: review of efficacy, safety, and regulation – grand rounds at University of California, San Francisco Medical Center. J Gen Intern Med. 2008;23(6):854–859.

22.

Foley

, Steel

, Cramer

, Wardle

, Adams

. Disclosure of complementary medicine use to medical providers: a systematic review and meta-analysis. Sci Rep. 2019;9(1):1573.